E Fund Management
JANX icon

E Fund Management’s Janux Therapeutics JANX Stock Holding History

E Fund Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-68,644
Closed -$1.85M – 413
2025
Q1 		$1.85M Buy
68,644
+4,076
+6% +$154K 0.09% 118
2024
Q4 		$3.46M Sell
64,568
-530
-0.8% -$28K 0.17% 71
2024
Q3 		$2.96M Buy
+65,098
New +$2.83M 0.15% 70

Other funds holding JANX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

E Fund Management's JANX Position: Q2 2025 in Review

E Fund Management sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 68,644 shares — an estimated $1.85M sold.

E Fund Management first reported a position in JANX in Q3 2024 and held it in 3 quarters. The position peaked at $3.46M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

  • E Fund Management reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
  • E Fund Management sold 68,644 Janux Therapeutics shares in Q2 2025, an estimated $1.85M.
  • E Fund Management first reported a position in Janux Therapeutics in Q3 2024 and held it in 3 quarters.
  • E Fund Management's Janux Therapeutics position peaked at $3.46M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on E Fund Management's 13F filing for Q2 2025, filed 15 Aug 2025.